Producer
Viatris Inc
US generic pharmaceutical company (spun off from Pfizer/Mylan 2020); first FDA approval for generic Restasis (cyclosporine ophthalmic emulsion) February 2022.
2
Inputs supplied
2
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Viatris Inc supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Viatris Inc makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Developed Markets (Generic + Branded Generics)
50%Emerging Markets
30%Janz (Biosimilars)
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Viatris' sildenafil product portfolio illustrates a single molecule serving completely different patient populations: (1) Erectile dysfunction (generic Viagra, 25-100mg): used by men with ED; one of the most recognizable drug names globally; (2) Pulmonary arterial hypertension / PAH (generic Revatio, 20mg): sildenafil at lower doses treats a rare and life-threatening lung blood pressure condition; PAH patients are often young women; (3) Off-label altitude sickness prevention: sildenafil is used off-label to prevent high-altitude pulmonary edema in mountain climbers and trekkers. The same sildenafil molecule treats a common male lifestyle condition (ED), a rare and fatal vascular disease (PAH), and an occupational hazard for high-altitude workers. Viatris also produces the EpiPen generic — the epinephrine auto-injector for severe allergic reactions (anaphylaxis) — and the generic Lipitor (atorvastatin for cardiovascular cholesterol management). One company makes both the emergency anaphylaxis response drug AND the lifestyle cardiovascular prevention drug AND the erectile dysfunction treatment, spanning emergency medicine, chronic disease management, and lifestyle pharmaceuticals.
Viatris Inc. ↗Origin2023
Viatris emerged from the 2020 merger of Mylan NV and Pfizer's Upjohn division — a combination of generic pharmaceutical heritage and legacy brand transition management. Mylan was founded in 1961 in White Sulphur Springs, West Virginia by two pharmacy graduates and grew into one of the world's largest generic pharmaceutical companies. Mylan became the defining pharmaceutical pricing controversy when it raised the price of EpiPen (epinephrine auto-injector) from approximately USD 100 per two-pack in 2007 to over USD 600 by 2016 — a 600% price increase over 9 years for a decades-old drug in a simple device. Mylan CEO Heather Bresch testified before Congress in 2016; Senator Bernie Sanders made Mylan/EpiPen pricing central to his presidential campaign pharmaceutical cost arguments. Mylan eventually settled with the DOJ for USD 465 million for EpiPen Medicaid overpricing. Pfizer's Upjohn brought the legacies of Lipitor (atorvastatin, world's best-selling drug by lifetime revenue) and Viagra (sildenafil, one of the most recognized drug brand names globally). The combined Viatris entity makes the generic EpiPen that Mylan once priced controversially, the generic Lipitor that replaced Pfizer's most profitable drug, and the generic Viagra.
Viatris Inc. ↗